Related references
Note: Only part of the references are listed.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
Thomas Berg et al.
JOURNAL OF HEPATOLOGY (2017)
When can we stop nucleoside analogues in patients with chronic hepatitis B?
Chern Hao Chong et al.
LIVER INTERNATIONAL (2017)
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
Marc Bourliere et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault et al.
HEPATOLOGY (2016)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S. K. Sarin et al.
HEPATOLOGY INTERNATIONAL (2016)
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B
P. Marcellin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Eradication Strategies for Chronic Hepatitis B Infection
Eleanor M. P. Wilson et al.
CLINICAL INFECTIOUS DISEASES (2016)
Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin et al.
GASTROENTEROLOGY (2016)
Adding Pegylated Interferon to Entecavir for Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Multicenter Randomized Trial (ARES Study)
Willem Pieter Brouwer et al.
HEPATOLOGY (2015)
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
Maria Buti et al.
HEPATOLOGY INTERNATIONAL (2015)
Parallel 34: Hepatitis B: Outcomes of Approved Therapy
HEPATOLOGY (2014)
Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients
Teerha Piratvisuth et al.
HEPATOLOGY INTERNATIONAL (2013)
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
Patrick Marcellin et al.
HEPATOLOGY INTERNATIONAL (2013)
Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2012)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2012)
Lamivudine Maintenance Beyond One Year After HBeAg Seroconversion Is a Major Factor for Sustained Virologic Response in HBeAg-Positive Chronic Hepatitis B
Hyun Woong Lee et al.
HEPATOLOGY (2010)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Durability of serologic response after lamivudine treatment of chronic hepatitis B
JL Dienstag et al.
HEPATOLOGY (2003)
Share Paper
